Laboratory Devoted to Improving the Quality
of Clinical Testing
At a ceremony at the University of California San Diego School
of Medicine, Waters Corporation (NYSE:WAT) officially welcomed the
university’s Center for Advanced Laboratory Medicine into the
Waters Centers of Innovation (COI) Program. Under the direction of
Professor Robert Fitzgerald, Director of Toxicology and Associate
Director of Clinical Chemistry, the laboratory develops, validates
and implements liquid chromatography-mass spectrometry (LC-MS)
diagnostic tests, including broad spectrum screens for drugs of
abuse, therapeutic drug monitoring and vitamin D testing.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160317005073/en/
Professor Robert Fitzgerald is Director
of Toxicology and Associate Director of Clinical Chemistry at the
University of California San Diego School of Medicine. (Photo:
Business Wire).
“We are very excited that Waters Corporation has recognized our
department’s work in developing mass spectrometry-based tests for
the clinical laboratory,” said Dr. Steven L. Gonias, Chair of the
Department of Pathology in the UC San Diego School of Medicine and
Chief of Pathology, at UC San Diego Health. “Dr. Fitzgerald and Dr.
David Herold of the UC San Diego School of Medicine have
contributed landmark studies focused on improving the accuracy of
diagnostic tests by applying mass spectrometry in new and
innovative ways. The potential to further improve patient care
through the expanded use of mass spectrometry is indeed
impressive.”
Dr. Fitzgerald is one of the world’s foremost experts in the use
of mass spectrometry for the analysis of testosterone and other
biologically important compounds. His laboratory is also a major
research center for studying cardiac biomarkers in diagnosing
disease and monitoring therapeutic interventions. In his role, Dr.
Fitzgerald oversees the activities of three clinical laboratories
for UC San Diego Health which together perform more than 4.5
million assays annually. Dr. Fitzgerald’s laboratory utilizes
several Waters tandem quadrupole and quadrupole time of flight mass
spectrometers, including the Xevo® TQ-S, Xevo G2 QTof™ and ACQUITY®
TQD.
“Waters has been an outstanding partner for us and has fully
supported us with robust instrumentation and solid technical
support,” Dr. Fitzgerald said. “I am particularly excited about the
aspect of our collaboration with Waters that allows us to train the
next generation of leaders in clinical chemistry, a field in which
mass spectrometry is becoming increasingly important.”
“It’s a pleasure to welcome the UC San Diego School of Medicine
into our COI Program. Largely due to the efforts of scientists like
Dr. Fitzgerald and his colleagues, the value of LC and MS in the
clinical laboratory has been clearly proven and is having lasting
benefits in the clinic,” said Eric Fotheringham, Director of the
Waters Centers of Innovation Program.
In 2013, Waters endowed a postdoctoral Clinical Chemistry
Fellowship at UC San Diego. The two-year program trains Fellows in
classical clinical chemistry, laboratory administration and
research practices to prepare them for directorship positions at
medical schools or hospital-based clinical chemistry
laboratories.
To salute the work of Prof. Fitzgerald and the Center for
Advanced Laboratory Medicine, Waters Corporation is sponsoring a
clinical science symposium. Titled Mass Spectrometry in the Modern
Clinical Laboratory, the event features presentations by noted
experts in clinical chemistry including Marilyn Huestis of the
University of Maryland Baltimore School of Medicine; Andy Hoofnagle
of the University of Washington; Kara Lynch of the University of
California, San Francisco; Gary Siuzdak of the Scripps Center for
Metabolomics; Frederick Strathman of the ARUP Institute for
Clinical and Experimental Pathology; Judy Stone of UC San Diego;
and Arash Zarrine-Afsar of the University of Toronto.
About the Center for Advanced Laboratory Medicine at UC San
Diego School of Medicine
The UC San Diego School of Medicine’s Center for Advanced
Laboratory Medicine (CALM) houses the Department of
Pathology’s Division of Laboratory Medicine. The facility features
state-of-the-art technologies used in diagnostic medicine and
pathology to support patient care and inquiry into emerging fields,
such as personalized medicine, genomics, clinical proteomics and
cell therapy.
About Waters Centers of Innovation Program
Established in 2010, Waters Centers of Innovation Program
recognizes accomplished scientists and their institutions for
research in the fields of the health sciences, pharmaceuticals,
chemical materials, food and environmental chemistry, mass
spectrometry and separations science. By partnering with leading
scientists and connecting them with experts in mass spectrometry
and separations science, Waters endeavors to bring about inspired
thinking that converts ideas into reality.
The participants in the Waters Centers of Innovation Program
include: Professor Ganesh Anand, National University of Singapore;
Professor Luiz Claudio Cameron, UniRio, Brazil; Professor David
Clemmer, Indiana University; Professor Daniel Tsun-Yee Chiu, Chang
Gung University; Dr. Joseph Dalluge, University of Minnesota; Dr.
Petur Weihe Dalsgaard, University of Copenhagen; Professor Marcos
Eberlin, University of Campinas, Brazil; Professor Chris Elliott,
Queen’s University Belfast; Professor John Engen, Northeastern
University; Prof. Rob Fitzgerald, University of California – San
Diego; Professor Albert J. Fornace, Jr., Georgetown Lombardi
Comprehensive Cancer Center; Professor David Goodlett and Dr.
Maureen Kane, University of Maryland; Professor De-an Guo, Shanghai
Institute of Materia Medica; Dr. Frank Gonzalez, National Cancer
Institute; Prof. Ron Heeren, Maastricht University; Prof. Sunghwan
Kim, Kyungpook National University, Seoul, Korea; Dr. Carlo R.
Largiadèr, Dr. Jean-Francois DuFour and Dr. Martin Fiedler,
Inselspital University Hospital, Bern, Switzerland; Professor Julie
Leary, University of California – Davis; Professor Amit Kumar
Mandal, St. John’s Research Institute, Bangalore, India; Professor
John McLean, Vanderbilt University; Professor Arthur Moseley, Duke
University; Professor Jeremy Nicholson, Imperial College London;
Dr. Devin Peterson, University of Minnesota; Associate Professor
Jessica Prenni, Colorado State University; Dr. Serge Rezzi, Nestle
Institute of Health Sciences; Dr. Ryan Rodgers, Future Fuels
Institute, Florida State University; Professor Pauline Rudd,
National Institute for Bioprocessing Research and Training;
Professor James Scrivens, University of Warwick; Professor Vladimir
Shulaev, University of North Texas; Dr. Norman Smith, Kings College
London; Professor Sarah Trimpin, Wayne State University; Professor
Bert van Bavel, NIVA, Oslo, Norway; Caroline West and Eric
Lesselier, University of Orleans, Orleans, France; and Prof. Vicki
Wysocki, The Ohio State University.
About Waters Corporation
(www.waters.com)
Waters Corporation (NYSE:WAT) develops and manufactures advanced
analytical and material science technologies for laboratory
dependent organizations. For more than 50 years, the company has
pioneered a connected portfolio of separations science, laboratory
information management, mass spectrometry and thermal analysis
systems.
Waters, ACQUITY, UltraPerformance LC, QTof and Xevo are
trademarks of Waters Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160317005073/en/
Waters CorporationBrian J. Murphy, +1-508-482-2614Public
Relationsbrian_j_murphy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2024 to May 2024
Waters (NYSE:WAT)
Historical Stock Chart
From May 2023 to May 2024